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Background: Hirayama disease (HD), amyotrophic lateral sclerosis (ALS) or cervical spondylotic amyotrophy (CSA)
may result in atrophy of intrinsic hand and forearm muscles. The incidence of HD is low, and it is rarely
encountered in the clinical setting. Consequently, HD is often misdiagnosed as ALS or CSA. It is important to
differentiate these diseases because HD is caused by a benign focal lesion that is limited to the upper limbs.
Methods: The thenar and hypothenar compound muscle action potential (CMAP) amplitude of the upper limbs of
100 HD, 97 ALS and 32 CSA cases were reviewed; 35 healthy individuals were included as controls. Seventy-eight
percent, 38% and 69% of patients with HD, ALS or CSA had unilateral involvement; the remaining patients were
affected bilaterally. Thenar and hypothenar CMAP amplitude evoked by ulnar stimulation was compared with CMAP
evoked by median stimulation.
Results: The ulnar/median CMAP ratio was found to be lower in HD (0.55 ± 0.41, P < 0.0001), higher in ALS (2.28 ± 1.15,
P < 0.0001) and no different in CSA (1.21 ± 0.53, P > 0.05) compared with the normal range from previous studies
(0.89-1.60) and with the healthy controls (1.15 ± 0.23). Conduction velocities of the sensory and motor nerves, the
amplitude of the sensory nerve action potential, and the CMAP amplitude of the unaffected limb were all normal.
Conclusions: The hand muscles were differentially affected between patients with HD, ALS and CSA. The ulnar/median
CMAP ratio could be used to distinguish these three diseases.
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Action potentialBackground
Hirayama disease (HD), also known as juvenile muscular
atrophy of the distal upper extremity, was first reported
by Hirayama et al. in 1959 as a benign focal motor
neuron disease characterized by unilateral atrophy of the
forearm ulnar muscle [1]. HD primarily affects males
(male:female ratio of 20:1) in their early years (predom-
inantly in the range of 15-25 years of age). Less than
1500 patients with HD were reported in the literature,
and these cases were mostly distributed in Japan, other
Asian countries, Europe and North America.
The contribution of family history was rarely observed
in HD. In addition, in most patients, the disease stabilizes* Correspondence: jianyuanjiang05@126.com
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unless otherwise stated.1-5 years after an insidious onset. However, in rare cases,
further amyotrophy progression has been reported. The
pathogenesis of HD remains obscure. Spinal cord ischemia
caused by cervical flexion, autoimmune diseases, idiopathic
disorders and gene mutations were proposed as causes of
the disease. The clinical features of HD are similar to those
of amyotrophic lateral sclerosis (ALS) and cervical spondy-
lotic amyotrophy (CSA). ALS manifests by the progressive
and malignant degeneration of motor nerves. The clinical
features are limb spasticity, focal or multifocal limb weak-
ness, wasting, dysarthria, dysphagia and dysmasesis [2]. In
about 40% of patients, ALS first affects the upper limbs,
and limb weakness is usually asymmetric in the early
stages of the disease.
In CSA, lesions to the anterior horn cells are a result
of an indirect insufficient blood supply due to cervicalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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intra- and extramedullary vessels with movements of the
cervical spine [3]. The clinical features of CSA include at-
rophy of the deltoid, scapular and interosseous muscles,
leading to upper limb muscular atrophy. A recent review
has shown that minimal or absent radicular pain or paraes-
thesia of the upper limbs was accompanied by spindle
spondylopatic radiculapathy or myelopathy [3,4]. CSA has
been classified as proximal or distal according to the pre-
dominant site of the lesion [5]. The affected muscles are
the deltoid and biceps (innervated by the C5 and C6 roots)
in proximal cases, while extensor and flexor muscles of the
fingers and intrinsic hand muscles (innervated by the C7-
T1 roots) are found in distal cases.
The incidence of HD is low, and it is rarely encoun-
tered in the clinical setting. Consequently, HD is often
misdiagnosed as ALS or CSA. It is important to differen-
tiate these diseases because HD is caused by a benign
focal lesion that is limited to the upper limbs. In con-
trast, ALS involves systemic muscles and may result in
respiratory failure, while CSA may lead to upper motor
neuron damage that could adversely affect the control of
the lower limbs.
In the present study, we compared the thenar and
hypothenar amplitudes of the upper limbs in patients
with HD, ALS or CSA, as well as in healthy controls [6].
Such detailed examination could enable the creation of
an index for the differentiation of these similar diseases.
Methods
Results from 229 patients who underwent thenar and
hypothenar compound muscle action potential (CMAP)
amplitude examinations between January 2007 and Janu-
ary 2013 at the Huashan Hospital, Fudan University
(Shanghai, China), were retrospectively reviewed. The
project was approved by the Human Ethics Committee
of the Huashan Hospital, Fudan University, China, and
the need for individual consent was waived since this
was a retrospective study. One hundred of these cases
were diagnosed as HD, 97 as ALS, and 32 as CSA. For
comparison, 35 healthy people who underwent CMAP
examination as part of their routine complete check-up
were included. Subjects with any relevant diseases or
systemic conditions were excluded. All participants
underwent electromyography of the thenar and hypothe-
nar muscles as conventional diagnosis method.
Criteria for diagnosis of HD were: 1) onset before
25 years of age; 2) unilateral or bilateral weakness of the
distal upper limbs, accompanied by distal amyotrophy of
the hand and forearm; 3) unaffected lower limbs; 4) uni-
lateral or asymmetric; and 5) stabilization of the disease
after an initial slow progression over several years [7,8].
In addition, lower cervical compression resulting from
anterior shifting of the posterior dura, and crescentabnormality posterior to the dura were evaluated by
MRI under neck flexion [9,10].
ALS was diagnosed according to the El Escorial criteria:
1) progressive muscle weakness and wasting; 2) fascicula-
tion and pyramidal sign; and 3) absence of sensory deficit
or sphincter dysfunction [11].
The criteria for CSA diagnosis were: 1) unilateral or
bilateral weakness of the distal upper limbs accompanied
by distal amyotrophy of the hand and forearm; 2) min-
imal or absence of sensory deficit of the upper limbs; 3)
hyperreflexia or normal function of the lower limbs; 4)
minimal or absence of radiative pain of the upper limbs;
and 5) a history of cervical spondylosis [12].
Exclusion criteria were: 1) history of syringomyelia,
spinal cord tumor or abnormalities of the cervical verte-
brae; 2) focal or multifocal neuropathy; 3) brachial
plexus lesion; 4) congenital muscular dystrophy; or 5) in-
jury or infection at presentation.
During motor nerve examination, thenar and hypothe-
nar CMAP values were recorded at the abductor pollicis
brevis (APB) and abductor digiti minimi (ADM) in re-
sponse to stimulation of the median and ulnar nerves,
respectively. The median nerve was stimulated at the
wrist and elbow. The ulnar nerve was stimulated at the
wrist, above and below the elbow (10 cm distance be-
tween above and below the elbow, under elbow flexion
at 90°). A surface electrode was placed at the belly of the
muscles (thenar and hypothenar) as the active or test
electrode, and at the tendon as the reference electrode.
In sensory nerve examination, the median and ulnar
nerves were stimulated at the wrist. By contrast, the sen-
sory nerve action potentials (SNAP) were recorded at
the index and little fingers with the active electrode
placed at the metacarpophalangeal joints, and the refer-
ence electrode placed 4 cm distal to the active electrode.
We measured CMAP and SNAP from the affected and
unaffected limbs of the patients with unilateral limb
involvement, and the conduction velocities of the motor
and sensory nerves. For those participants who had bilat-
eral upper limbs involvement, the amplitudes of the most
affected hand were recorded. In the healthy group, nerve
conduction studies were all performed in the left hand. For
each parameter, we calculated the ulnar/median (U/M) ra-
tios. A U/M CMAP amplitude ratio of <0.6 or >1.7 was
regarded as abnormal [13,14].
Student’s t-tests and Pearson’s rank correlation coeffi-
cients were used for statistical analysis. A P-value <0.05
was considered statistically significant.
Results
Demographic data are presented in Table 1. Seven of the
97 patients with ALS (3 with carpal tunnel syndrome, and
4 with multiple peripheral neuropathy), and 2 of the 32 pa-
tients with CSA (1 with cubital tunnel syndrome, and 1
Table 1 Demographic characteristics of patients with HD, ALS or CSA
HD ALS CSA Normal controls
N 100 90 30 35
Male/Female 95/5 52/38 19/11 25/10
Mean onset age (years) 19.8 (14-27) 56.4 (36-72) 54.8 (42-76) 27.2(20-41)
Mean duration (months) 14.5 (6-30) 24.8 (3-48) 26.2 (3-60)
Unilateral upper limb affected 78 37 22
Bilateral upper limbs affected 22 53 8
HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical spondylotic amyotrophy.
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study due to complications. Among the included patients,
78 of the 100 (78.0%) patients with HD, 37 of the 90
(41.1%) patients with ALS, and 22 of the 32 (68.8%) pa-
tients with CSA were affected unilaterally, while the
remaining cases were affected bilaterally.
Nerve conduction was successfully recorded for the
sensory and motor nerves in all patients (Table 2). We
observed significantly lower ulnar CMAP amplitudes
and slightly lower median CMAP amplitudes for the
affected limbs in patients with HD, resulting in a mean
U/M CMAP ratio of 0.55 ± 0.41, which was significantly
lower than the previously reported normal ratio of 0.89-
1.60 [13,14], or the ratio of 1.15 ± 0.23 observed in the
healthy controls. The difference between the median and
the median ulnar CMAP amplitudes was 4.5 ± 0.3 mV
(range: -3.0 - 12.5 mV). An abnormal median CMAP
amplitude (<6.0 mV) was found in 23 patients (23%) and
an abnormal ulnar CMAP amplitude (<5.5 mV) was
found in 83 patients (83%) of the HD group.
We also observed slightly lower ulnar and significantly
lower median CMAP amplitudes in the affected limbs of
patients with ALS, resulting in a mean U/M CMAP ratio
of 2.28 ± 1.25, which was significantly higher than the
normal ratio. The difference between the median and
the median ulnar CMAP amplitudes was -1.3 ± 1.6 mV
(range -6.7 - 4.5 mV). In the ALS group, we foundTable 2 Motor nerve conduction tests in patients with HD, AL
Median nerve
Amplitude (mV) CV (m/s)
HD Affected limb 8.2 ± 3.9& 59.3 ± 4.3
Healthy limb 10.3 ± 2.4 60.2 ± 3.5
ALS Affected limb 2.3 ± 2.2*& 55.5 ± 4.5*&
Healthy limb 7.9 ± 2.4# 54.8 ± 3.9*
CSA Affected limb 4.5 ± 3.1*& 57.4 ± 5.2
Healthy limb 8.2 ± 2.0# 57.2 ± 3.2*
Normal controls 9.0 ± 1.5 59.8 ± 3.1
*P < 0.0001, the affected (healthy) limbs of patients with ALS or CSA vs. the affected
#P < 0.001, the affected (healthy) limbs of patients with ALS or CSA vs. the affected
&P < 0.0001, the affected limbs of patients with HD, ALS or CSA patients vs. the limb
HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical spondylotic aabnormal median CMAP amplitude in 66 (73%) patients,
and abnormal ulnar CMAP amplitude in 48 (54%) patients.
Slightly decreased ulnar and median CMAP amplitudes
were found in the affected limbs of patients with CSA,
resulting in a mean U/M CMAP ratio of 1.21 ± 0.53, which
was comparable to the normal ratio. The difference be-
tween the median and the median ulnar CMAP ampli-
tudes was 0.4 ± 1.6 mV (range -2.7 - 4.6 mV). Abnormal
median CMAP amplitude was found in 16 patients (53%),
and abnormal ulnar CMAP amplitude was found in 17 pa-
tients (57%) in the CSA group. Additionally, significant dif-
ferences were found between the U/M CMAP ratios of the
three diseases (P < 0.0001), as well as between patients with
HD and controls (P < 0.0001), and between patients with
ALS and controls (P < 0.0001).
The motor nerve conduction velocities (CV) was mar-
ginally higher than the lower limit of the normal range
in patients with ALS, but was found to be normal in pa-
tients with HD or CSA. Additionally, lower ulnar me-
dian CVs in 6 (0.07) patients with ALS and lower
median CVs in 8 (0.10) patients with ALS were ob-
served. The extent of these lower values was very similar,
and the U/M CV ratio was about 1.0. A similar ratio
was found in patients with HD or CSA.
The U/M CMAP ratios are presented in Table 3. Pa-
tients with ALS showed a positive correlation between
the ulnar CMAP amplitude and the ulnar motor nerveS or CSA
Ulnar nerve U/M ratio
Amplitude (mV) CV (m/s) Amplitude CV
3.2 ± 2.6& 60.3 ± 5.5 0.55 ± 0.41& 1.02 ± 0.11
9.0 ± 1.9 59.3 ± 4.2 0.98 ± 0.22 1.03 ± 0.11
4.8 ± 3.5*& 56.6 ± 6.0*& 2.28 ± 1.25*& 1.10 ± 0.18
8.4 ± 2.4 55.2 ± 4.2# 1.12 ± 0.32 1.04 ± 0.14
4.9 ± 3.1*& 55.1 ± 4.1*& 1.21 ± 0.53* 0.95 ± 0.13
7.8 ± 1.8# 55.2 ± 4.3* 0.97 ± 0.34 0.93 ± 0.17
9.5 ± 1.8 60.2 ± 3.2 1.15 ± 0.23 1.01 ± 0.12
(healthy) limbs of patients with HD.
(healthy) limbs of patients with HD.
s of normal controls.
myotrophy; CV, conduction velocities; U/M, ulnar/median.
Table 3 U/M CMAP ratio in patients with HD, ALS or CSA
U/M CMAP ratio
<0.6 0.6-1.7 >1.7
HD Affected limb 62 28 10
Healthy limb 0 78 0
ALS Affected limb 3 54 33
Healthy limb 0 37 0
CSA Affected limb 1 27 2
Healthy limb 0 22 0
Normal controls Healthy limb 0 35 0
HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical
spondylotic amyotrophy; CV, conduction velocities; U/M, ulnar/median; CMAP,
compound muscle action potential.
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in patients with HD or CSA. We found sixty-six affected
limbs with an abnormally low ratio (<0.6) (62 patients
with HD, 3 patients with ALS and 1 patient with CSA).
Forty-five affected limbs exhibited an abnormally high
ratio (>1.7) (10 patients with HD, 33 patients with ALS
and 2 patients with CSA). Moreover, normal CMAP and
motor nerve CVs were observed for all unaffected limbs.
The results of the sensory nerve conduction tests are
presented in Table 4. We found normal SNAP ampli-
tudes and sensory nerve CVs in all patients. Median and
ulnar SNAP were different between controls and all
three disease groups (P < 0.0001), but the U/M ratio was
similar between the four groups.
Discussion
Compared with healthy subjects, we observed that the
U/M CMAP ratio was lower in patients with HD, higher
in patients with ALS, and in the normal range for pa-
tients with CSA. Although both thenar and hypothenar
muscles are innervated by the C8/T1 segments, different
patterns of muscle weakness and wasting were observed
between HD, ALS and CSA. Compared with thenar
muscles, more severe influences on hypothenar musclesTable 4 Sensory nerve conduction tests in patients with HD, A
Median nerve
Amplitude (μV) CV (m/s)
HD Affected limb 50.1 ± 13.2& 62.1 ± 6.4&
Healthy limb 50.4 ± 12.1 61.2 ± 6.4
ALS Affected limb 31.7 ± 14.3*& 57.5 ± 8.3*&
Healthy limb 37.6 ± 12.3* 57.8 ± 5.9*
CSA Affected limb 38.9 ± 13.2*& 57.6 ± 5.7*&
Healthy limb 38.2 ± 11.8* 57.2 ± 4.3*
Normal controls 45.6 ± 15.2 60.7 ± 5.2
*P < 0.0001, the affected (healthy) limbs of patients with ALS or CSA patients vs. the
&P < 0.0001, the affected limbs of patients with HD, ALS or CSA vs. the limbs of nor
HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical spondylotic awere also found in patients with HD. The ADM ampli-
tude was previously reported to be marginally lower
than the APB amplitude in normal subjects, which pro-
duced a U/M CMAP ratio of 0.82 (range: 0.6 - 1.7)
[13,14]. In the present study, the U/M CMAP ratio was
less than 0.6 in 62 patients with HD (61%) and supported
the more severe effects exhibited by the hypothenar
muscle.
The thenar muscle is more vulnerable in patients with
ALS, which involves greater decreases in the motor unit
for APB than that seen for ADM. A mean APB-ADM
amplitude difference of -1.7 mV, a mean APB/ADM
CMAP ratio of 0.7 and significantly lower APB/ADM
CMAP ratios have been reported in 41% of patients of a
prospective study [13]. In our study, the mean difference
was -1.3 mV, while the mean U/M CMAP ratio was
2.28, with a significantly higher U/M CMAP ratio found
in 37% of patients. These observations confirmed the
importance of the more severe involvement of the the-
nar muscle in patients with ALS.
The thenar and hypothenar muscles are affected to a
similar extent in patients with CSA. In our study, the
U/M CMAP ratio was in the normal range in 27 patients
(90%). However, a mean APB-ADM amplitude difference
of 2.6 mV, which was consistent with a more severe at-
rophy of the hypothenar muscle, was previously reported
by Kuwabara et al. [13]. This discrepancy may result
from sampling differences between the two studies. For
example, patients with distal CSA were included in our
study while Kuwabara et al. [13] excluded them.
In contrast, the hypothenar muscles are affected more
severely in patients with HD. In our study, more severe ef-
fects on the hypothenar muscle were found in the affected
limbs of only 3 patients with ALS (2%) and only 1 patient
with CSA (3%). In addition, 94% of the affected limbs
showing a U/M CMAP ratio <0.6 were found in HD. Thus,
a U/M CMAP ratio <0.6 is strongly indicative of a diagno-
sis of HD but not of ALS. Simultaneously, more severe ef-
fects on the thenar muscle were found in the affectedLS or CSA
Ulnar nerve U/M ratio
Amplitude (μV) CV (m/s) Amplitude CV
42.5 ± 13.7& 60.1 ± 5.5 0.9 ± 0.4 1.0 ± 0.1
44.9 ± 11.4 60.5 ± 6.2 0.9 ± 0.3 1.0 ± 0.1
31.9 ± 13.4*& 56.6 ± 6.9*& 0.9 ± 0.3 0.9 ± 0.1
34.8 ± 13.1* 56.2 ± 5.2* 0.9 ± 0.3 1.0 ± 0.1
36.5 ± 11.3*& 57.1 ± 4.5*& 0.9 ± 0.2 0.9 ± 0.1
37.5 ± 11.7* 57.2 ± 4.3* 0.9 ± 0.3 0.9 ± 0.2
38.1 ± 11.1 60.5 ± 5.2 0.9 ± 0.2 0.9 ± 0.1
affected (healthy) limbs of patients with HD.
mal control.
myotrophy; CV, conduction velocities; U/M, ulnar/median.
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CSA (4%). Consequently, only 74% of all the affected limbs
showing a U/M CMAP ratio >1.7 was found in ALS and,
importantly, this observation disqualified the U/M CMAP
ratio criteria in the diagnosis of ALS.
Currently, the pathogenesis of both HD and CSA re-
mains unclear. Two main hypotheses for understanding
HD pathogenesis include the “dynamics” hypothesis of
Hirayama and the “imbalanced growth” hypothesis of
Toma. The former involves a circulation deficit during
neck flexion, which results in degeneration of the anter-
ior horn and neurogenic atrophy of the innervated mus-
cles [15,16]. The circulation deficit of the spinal anterior
artery has been suggested by angiography to be a prom-
inent factor in the degeneration process [17,18]. The im-
balanced growth of both the spinal cord and the spinal
dura was proposed by Toma et al. to be a possible cause,
based on the growth curves of 7 patients. It is proposed
that the inflexible dura will compress the spinal cord
during neck flexion, and repeated neck flexion will lead
to microinjuries and finally to spinal cord atrophy [19].
Similarly, specific compression of the ventral roots in
cervical spondylosis was suggested by Keegan et al. to
result in separative motor neuron injury of the upper
limbs in CSA [20]. An alternative explanation involves a
deficiency in blood supply, and subsequent lesions of the
anterior horn cells following compression [21].
The differences between HD and CSA have been less
discussed. Both diseases share similar pathogenesis and
similar clinical features, but they have distinct ages of
onset. HD predominantly affects juveniles, while CSA
mostly affects the aged population. In our study, the
mean age of onset in patients with HD was 19.8 years,
while it was 54.8 years in CSA. However, there remains
some controversy in the literature: is HD a juvenile form
of CSA or is CSA a aged form of HD [22,23]?Conclusions
In conclusion, the different patterns of hand muscle at-
rophy indicate that HD, CSA and ALS are different dis-
eases with their own distinct pathogenesis. Therefore,
the U/M CMAP ratio could be considered as a criterion
in the differential diagnosis of HD, ALS and CSA. A low
U/M ratio is suggestive of HD, while a high U/M ratio is
suggestive of ALS.Abbreviations
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